# 5 Exciting Insights from the MedCan 3 Trial

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/medcan3-trial-cancer-symptoms/
> **Published:** 2025-03-17T13:04:41-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:15:45-04:00
> **Clinical Summary:** Read the MedCan 3 trial’s exciting insights on THC/CBD for cancer symptom relief. Learn what sets it apart and its goals in improving patient care.

---

****

Table of Contents

- [MedCan 3: A Landmark Study on Medicinal Cannabis for Cancer Symptom Management](#MedCan_3_A_Landmark_Study_on_Medicinal_Cannabis_for_Cancer_Symptom_Management)[Key Features of the MedCan 3 Study](#Key_Features_of_the_MedCan_3_Study)[Study Design](#Study_Design)
- [Primary Objective](#Primary_Objective)
- [Sleep Sub-Study](#Sleep_Sub-Study)
- [Data Collection and Management](#Data_Collection_and_Management)
- [Post-Trial Care](#Post-Trial_Care)
- [How MedCan 3 Improves Upon Previous Research](#How_MedCan_3_Improves_Upon_Previous_Research)
- [What the Study Doesn’t Cover](#What_the_Study_Doesnt_Cover)[Medical & Scientific Gaps](#Medical_Scientific_Gaps)
- [Social & Cultural Factors Not Considered](#Social_Cultural_Factors_Not_Considered)
- [Key Questions MedCan 3 Aims to Answer](#Key_Questions_MedCan_3_Aims_to_Answer)
- [Primary Research Question](#Primary_Research_Question)
- [Secondary Research Questions](#Secondary_Research_Questions)
- [Sleep Sub-Study Question](#Sleep_Sub-Study_Question)
- [Exploratory Questions](#Exploratory_Questions)
- [Why This Study Matters](#Why_This_Study_Matters)
- [References & Further Reading](#References_Further_Reading)
- [Related](#Related)

## MedCan 3: A Landmark Study on Medicinal Cannabis for Cancer Symptom Management

 

[More access here](https://cedclinic.com/)

 

The **MedCan 3** study is a highly anticipated clinical trial investigating the potential of medicinal cannabis to alleviate symptoms in patients with advanced cancer. What sets this trial apart is its **comprehensive, patient-centered approach**—not only does it assess overall symptom burden, but it also includes a dedicated sub-study on **sleep quality**.

 

Unlike prior research, MedCan 3 features a **patient-determined titration phase** and a **teletrial model** to ensure accessibility for a diverse population. The study aims to provide **rigorous, high-quality evidence** on the efficacy and safety of a **1:20 THC/CBD formulation**, potentially revolutionizing symptom management in oncology care.

 

### Key Features of the MedCan 3 Study

 

#### Study Design

 

MedCan 3 is a **pragmatic, multicenter, randomized, placebo-controlled trial** testing escalating doses of a **1:20 THC/CBD medicinal cannabis preparation**. The patient-determined **titration phase** allows participants to adjust doses based on their unique responses, mirroring real-world use.

 

### Primary Objective

 

The primary aim is to evaluate whether **self-titrated** THC/CBD reduces **total symptom distress score (TSDS)** more effectively than a placebo. Additionally, the study assesses:

 

◊ The **median effective dose** within the pre-specified range.

 

◊ The impact of THC/CBD on **individual symptoms** at days 7, 21, and 28.

 

◊  Changes in **physical and emotional health, global impression of change, anxiety, depression, and sleep quality**.

 

◊  **Safety and tolerability** profiles.

 

### Sleep Sub-Study

 

 

A key innovation in MedCan 3 is its **dedicated sleep sub-study**, which examines whether medicinal cannabis can improve **sleep disturbances** in cancer patients. The trial utilizes:

 

**◊ Actigraphy** (a non-invasive method to monitor sleep-wake cycles).

 

**◊** The **Insmnia Severity Index (ISI)** to measure subjective sleep quality.

 

### Data Collection and Management

 

 

Patient data is collected from **outpatient clinics** and medical records, ensuring **secure storage** and adherence to compliance protocols.

 

### Post-Trial Care

 

 

Although participants will not be financially compensated, they may gain **access to cannabinoid-based treatments** through other studies or **reduced-cost programs**. The study investigators will continue prescribing cannabis as **authorized healthcare providers**.

 

**Dissemination of Results******

 

Findings will be shared through **scientific publications, media releases, and social media**, ensuring accessibility to both the medical community and the public.

 

### 

### 

### How MedCan 3 Improves Upon Previous Research

 

 

While past studies have explored cannabis for cancer symptom relief, MedCan 3 introduces **several groundbreaking features**:

 

 1. **Total Symptom Burden as the Primary Outcome******

 

Previous research often focused on **specific symptoms (e.g., pain, nausea)** rather than overall **symptom distress**. MedCan 3 takes a **holistic approach**, aligning with how patients experience symptom relief.

 

 

 2. **Rigorous Sleep Sub-Study******

 

Many trials have **anecdotally** noted improved sleep with cannabis, but MedCan 3 **objectively measures sleep outcomes** using **actigraphy and ISI scores**.

 

 

 3. **Innovative Study Design******

 

◊ The **teletrial model** expands accessibility, reaching diverse and underserved populations.

 

◊ The **self-titration phase** mimics **real-world dosing practices** rather than relying on fixed doses.

 

 4. **Comprehensive Post-Trial Care******

 

MedCan 3 prioritizes **continued patient support**, unlike past trials that left participants without follow-up options.

 

 

### 

### 

### What the Study Doesn’t Cover

 

 

Despite its strengths, MedCan 3 **does not address several critical areas**, leaving opportunities for future research:

 

#### Medical & Scientific Gaps

 

 

 

**◊ Long-Term Effects**: MedCan 3 focuses on short-term outcomes, leaving questions about **long-term [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and symptom relief**.

 

**◊ Cancer Type-Specific Effects: **The study applies broadly to advanced cancer patients but does not explore **cannabis’ effects on specific cancer types**. 

 

**◊ Drug Interactions**: The study does not examine how cannabis interacts with **chemotherapy, immunotherapy, or targeted cancer treatments**.

 

**◊ Optimal Dosing & Administration**: More research is needed to refine **dosing guidelines** and determine the most effective **administration routes (oral, sublingual, inhalation, etc.)**.

 

**◊ Psychosocial & [Quality of Life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) Outcomes**: While total symptom burden is a primary measure, broader **psychosocial impacts** are not a key focus.

 

### 

### Social & Cultural Factors Not Considered

 

 

**◊ Cultural Attitudes Toward Cannabis**: Perspectives on medicinal cannabis vary across **regions and demographics**, but this is not explored.

 

**◊ Socioeconomic Status: **The study does not account for economic barriers affecting [cannabis access](https://cedclinic.com/medical-cannabis-delivery-services-growth-dmv-jamaica/).  

 

**◊ Racial & Ethnic Disparities**: The study does not investigate potential **racial disparities in treatment access or response**.

 

**◊ Gender & Sexual Orientation**: There is no analysis of how **gender identity or sexual orientation** may influence symptom burden or cannabis efficacy.

 

**◊ Parenting & Caregiving**: The impact on **patients who are caregivers or parents** is not specifically addressed.

 

**◊ Healthcare Provider Education**: No component of the trial focuses on **training physicians and nurses** in prescribing cannabis effectively.

 

### Key Questions MedCan 3 Aims to Answer

 

This study seeks to provide **definitive answers** on THC/CBD’s role in cancer care by addressing the following:

 

### Primary Research Question

 

◊ **Does self-titrated, increasing doses of a 1:20 THC/CBD oral suspension significantly reduce total symptom distress score (TSDS) compared to placebo by day 14?******

 

### Secondary Research Questions

 

 

 

**◊ ****How does THC/CBD impact individual symptom scores** at days 7, 21, and 28?

 

**◊ What is the Median Effective Dose** within the specified range? 

 

◊  **Does it improve overall well-being, anxiety, depression, and emotional health?******

 

◊ **What are the safety and tolerability profiles of the formulation?******

### 

### Sleep Sub-Study Question

 

 

◊ **Can the THC/CBD formulation improve sleep quality,** as measured by actigraphy and ISI scores?

 

 

### Exploratory Questions

 

 

◊ **Do patient characteristics (e.g., age, cancer type, prior cannabis use) influence treatment response?******

 

◊ **How do patients perceive efficacy and tolerability compared to placebo?******

 

◊ **What are the long-term effects on symptom burden and quality of life?******

 

 

By answering these questions, MedCan 3 aims to **inform future clinical practice, guide policy, and shape future research** on cannabis for [cancer symptom management](https://cedclinic.com/cannabis-consumption-cancer-immunotherapy-outcomes/).

 

### 

### 

### Why This Study Matters

 

 

MedCan 3 has the potential to **transform cancer care** by addressing **longstanding gaps in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/)**. By using a **rigorous study design, real-world dosing approach, and innovative teletrial model**, this trial could provide **the strongest evidence to date** on how THC/CBD affects symptom distress and sleep in advanced cancer patients.

 

 

Its findings could lead to:

 

 

◊ **Better-informed clinical guidelines** for prescribing cannabis.

 

**◊ Stronger policy recommendations** for integrating cannabis into palliative care.

 

**◊ Improved access for patients in need**, particularly in telehealth and underserved populations.

 

 

 

With results expected in the near future, **MedCan 3 stands as one of the most exciting and impactful cannabis studies in oncology today**.

 

### References & Further Reading

[National Cancer Institute](https://www.cancer.gov/about-cancer/treatment/cam/patient/cannabis-pdq)

[ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT03529448)

Creating Big Data in Cannabis

[CED Clinic’s Research Library](https://cedclinic.com/resources/cannabis-literature-library/)

[EO Care Platform](https://www.eo.care/web/home)

 

 

 

 

 

### 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).